Earnings

MIRA Pharmaceuticals Submits Phase 2a Ketamir‑2 Protocol For CIPN To IRB, Incorporating FDA Feedback And Targeting Q1 2027 Site Initiation

Sep 17, 2026 · 08:38 AM ET· updated 2h ago

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) ("MIRA" or the "Company"), a clinical-stage pharmaceutical company developing novel oral small-molecule therapeutics, today announced that, following review and

Why It Matters

MIRA submitted a plan to test a new nerve pain medicine. The company listened to FDA feedback and plans to start patients in early 2027.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

MIRA0.74

+0.02 (+2.28%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.